Ortec launches OrCel through PDI:
This article was originally published in Clinica
Ortec International is to launch OrCel, a biologically active wound agent, from this quarter, with a dedicated sales force from sales and marketing company PDI. The two companies will target the $100 million donor site burn market. New York-based Ortec says its product is the only one containing living human cells that is FDA-approved for healing donor site wounds in burn patients. At a later stage, Ortec plans "a collaboration with or acquisition by a large, woundcare focused marketing and distribution company" for the venous and diabetic ulcer markets.